ArticleJournal of thoracic disease2025
P3H1 promotes malignant progression of esophageal squamous cell carcinoma (ESCC) and modulates the immune microenvironment.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of left gastric artery lymph node metastasis in patients with thoracic esophageal squamous cell carcinoma: a retrospective cohort study.Journal of thoracic disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is the predominant subtype of esophageal cancer (EC) in China and carries high lethality, in part because early disease is typically asymptomatic and thus diagnosed at advanced stages. To address the need for new biomarkers and targets, we investigated prolyl 3‑hydroxylase 1 (P3H1), a collagen‑modifying enzyme with emerging roles in cancer, aiming to clarify its contribution to ESCC progression and its potential as a prognostic biomarker and therapeutic target. Methods: We integrated clinical and transcriptional profiles of ESCC from public datasets [The Cancer Genome Atlas (TCGA); Gene Expression Omnibus (GEO) cohorts GSE53623 and GSE53624] and single‑cell RNA‑seq data (GSE154763) to evaluate P3H1 expression, clinicopathologic associations, survival, and diagnostic performance. Results: P3H1 was significantly overexpressed in ESCC versus normal tissues across TCGA and GEO, confirmed by IHC of tumor/peritumoral pairs and by elevated mRNA/protein in ESCC cell lines relative to HET‑1A. Higher P3H1 is associated with larger tumor size, lymph‑node metastasis, advanced tumor-node-metastasis (TNM) stage, and poorer survival. Diagnostic performance for ESCC was high. In KYSE‑180 cells, shRNA knockdown of P3H1 reduced proliferation (CCK-8, colony formation) and impaired migration/invasion (wound healing, Transwell). Immune deconvolution linked P3H1 to multiple immune‑cell compartments-particularly T‑cell signatures-and showed positive correlations with checkpoint genes including HAVCR2 and SIGLEC15. Single‑cell analyses indicated enriched P3H1 expression in plasmacytoid dendritic cells (pDCs), suggesting a role in shaping an immunoregulatory milieu that may favor tumor progression. Conclusions: Our study demonstrates that P3H1 is markedly upregulated in ESCC and contributes to tumor proliferation, migration, and invasion. In addition, P3H1 shows strong associations with immune infiltration and checkpoint pathways, suggesting a role in shaping the tumor immune microenvironment. These findings support P3H1 as a potential diagnostic biomarker and therapeutic target in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.